These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22695340)

  • 1. Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease.
    Berti V; Polito C; Borghammer P; Ramat S; Mosconi L; Vanzi E; De Cristofaro MT; De Leon M; Sorbi S; Pupi A
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):299-308. PubMed ID: 22695340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages.
    Borghammer P; Chakravarty M; Jonsdottir KY; Sato N; Matsuda H; Ito K; Arahata Y; Kato T; Gjedde A
    Brain Struct Funct; 2010 May; 214(4):303-17. PubMed ID: 20361208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose metabolism in small subcortical structures in Parkinson's disease.
    Borghammer P; Hansen SB; Eggers C; Chakravarty M; Vang K; Aanerud J; Hilker R; Heiss WD; Rodell A; Munk OL; Keator D; Gjedde A
    Acta Neurol Scand; 2012 May; 125(5):303-10. PubMed ID: 21692755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.
    González-Redondo R; García-García D; Clavero P; Gasca-Salas C; García-Eulate R; Zubieta JL; Arbizu J; Obeso JA; Rodríguez-Oroz MC
    Brain; 2014 Aug; 137(Pt 8):2356-67. PubMed ID: 24951642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease.
    Blum D; la Fougère C; Pilotto A; Maetzler W; Berg D; Reimold M; Liepelt-Scarfone I
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2387-2395. PubMed ID: 30008111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.
    Matthews DC; Lerman H; Lukic A; Andrews RD; Mirelman A; Wernick MN; Giladi N; Strother SC; Evans KC; Cedarbaum JM; Even-Sapir E
    Neuroimage Clin; 2018; 20():572-579. PubMed ID: 30186761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease.
    Klein RC; de Jong BM; de Vries JJ; Leenders KL
    Mov Disord; 2005 Aug; 20(8):1021-30. PubMed ID: 15858809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.
    Garcia-Garcia D; Clavero P; Gasca Salas C; Lamet I; Arbizu J; Gonzalez-Redondo R; Obeso JA; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1767-77. PubMed ID: 22872307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET.
    Berding G; Odin P; Brooks DJ; Nikkhah G; Matthies C; Peschel T; Shing M; Kolbe H; van Den Hoff J; Fricke H; Dengler R; Samii M; Knapp WH
    Mov Disord; 2001 Nov; 16(6):1014-22. PubMed ID: 11748732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study.
    Bohnen NI; Koeppe RA; Minoshima S; Giordani B; Albin RL; Frey KA; Kuhl DE
    J Nucl Med; 2011 Jun; 52(6):848-55. PubMed ID: 21571793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample.
    Tomše P; Jensterle L; Grmek M; Zaletel K; Pirtošek Z; Dhawan V; Peng S; Eidelberg D; Ma Y; Trošt M
    Neuroradiology; 2017 May; 59(5):507-515. PubMed ID: 28386687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson's disease].
    Homenko JG; Susin DS; Kataeva GV; Irishina JA; Zavolokov IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):46-51. PubMed ID: 28638030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].
    Arahata Y; Kato T; Tadokoro M; Sobue G
    Nihon Rinsho; 1997 Jan; 55(1):222-6. PubMed ID: 9014454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illusory misidentifications and cortical hypometabolism in Parkinson's disease.
    Ishioka T; Hirayama K; Hosokai Y; Takeda A; Suzuki K; Nishio Y; Sawada Y; Takahashi S; Fukuda H; Itoyama Y; Mori E
    Mov Disord; 2011 Apr; 26(5):837-43. PubMed ID: 21370270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease.
    Tang Y; Ge J; Liu F; Wu P; Guo S; Liu Z; Wang Y; Wang Y; Ding Z; Wu J; Zuo C; Wang J
    PLoS One; 2016; 11(4):e0152716. PubMed ID: 27064684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment.
    Lyoo CH; Jeong Y; Ryu YH; Rinne JO; Lee MS
    Eur Neurol; 2010; 64(2):65-73. PubMed ID: 20606450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism.
    Pappatà S; Santangelo G; Aarsland D; Vicidomini C; Longo K; Bronnick K; Amboni M; Erro R; Vitale C; Caprio MG; Pellecchia MT; Brunetti A; De Michele G; Salvatore M; Barone P
    Neurology; 2011 Oct; 77(14):1357-62. PubMed ID: 21940621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease.
    Borghammer P; Cumming P; Aanerud J; Gjedde A
    Neuroimage; 2009 Apr; 45(2):249-57. PubMed ID: 18718541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease.
    Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Suzuki K; Hasegawa T; Aoki M; Takeda A; Mori E
    J Neurol Sci; 2017 Jan; 372():288-293. PubMed ID: 28017230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.